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Abstract
The process of hunt of a lead molecule is a long and a tedious process and one is
often demoralized by the endless possibilities one has to search through. Fortu-
nately, computational tools have come to the rescue and have undoubtedly played a
pivotal role in rationalizing the path to drug discovery. Of all techniques, molecular
docking has played a crucial role in computer aided drug design and has swiftly
gained ranks to secure a valuable position in the modern scenario of structure-based
drug design. In this chapter, the principle, sampling algorithms, scoring functions
and diverse available software’s for molecular docking have been summarized. We
demonstrate the interplay of docking, classical techniques of structure-based design
and X-ray crystallography in the process of drug discovery. In addition, we dwell
upon some of the limitations faced in docking studies. Finally, several success
stories of molecular docking approaches in drug discovery have been highlighted,
concluding with remarks on molecular docking for the future.
Keywords: molecular docking, virtual screening, drug discovery, computer aided
drug design, conformational sampling, scoring functions
1. Introduction
The path to drug discovery is a long, challenging & arduous task not to mention
the overburdening finances it demands. As of 2014, the average cost of developing a
new drug from scratch was found to be an estimated $2.5 billion, an increase of
145% from the previous study done by the same organization in 2003. The major
reasons for this drastic increase in the cost is mainly attributed to high failure rate of
drugs among others [1]. Understanding of the drug discovery process is important
to handle the challenges faced by the pharma companies in terms of cost and
innovation.
The process of identifying a target, synthesizing an active compound with
suitable characteristics like minimal toxicity, high bioavailability, cost-effective
synthesis, etc., and finally developing it to introduce in the market is a time-
consuming, extremely complex and risky endeavor [2]. Initially, a target is identi-
fied which plays a key role in progress of the disease. Once a link between the target
and the disease has been established, the next step is to identify potential candidates
which can stop or reverse the progress of the disease [3]. This process starts with the
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discovery of molecules that show efficacy in a simple screen, called “hits.” Screen-
ing is a process in which normally a large number of compounds from natural
products and online databases are examined for biological activity in high-
throughput assays. This step in the drug discovery process is very crucial and
demands maintaining huge molecular libraries and carrying out thousands or mil-
lions of assays, which leaves the academicians and small pharmaceutical companies
at a disadvantage and also shoots up the cost for larger industries. Next, the “hits”
found are chemically modified to give improved pharmaceutical properties, such
compounds are often called “leads.” But, it is quite apparent that the method stated
above for discovery of a drug has a number of pitfalls. From an academic point of
view, carrying out high throughput screens (HTS) is costly, time-consuming and
not feasible; while, from an industrial perspective, it does nothing to improve the
eminent danger of market saturation.
Truly innovative and blockbuster drugs are what drive the pharmaceutical
industry forward but, over the past few years introduction of new molecular enti-
ties (NMEs) has vastly reduced. For example, in 2007 only 19 NMEs were approved
by the US Food and Drug Administration (FDA), the least since 1983 [4]. Cur-
rently, and even in the future it is expected that only slight modifications of the
existing blockbuster drugs would be carried out which would further aggravate this
problem [5]. HTS would not help in either curbing the rising costs of discovering
hits or the problem of finding truly innovative and blockbuster NMEs, the two
major hurdles that the pharmaceutical industry faces now-a-days.
To overcome these challenges, molecular docking is an exemplary tool. During
the first step to find hits from existing chemicals for a drug discovery and develop-
ment project, virtual screening (VS) is a perfectly viable and an alternative or
complementary approach to HTS for fulfilling the screening of thousands or mil-
lions of compounds within a few days. In addition, the speed of VS helps in kick-
starting projects for newer targets for which no leads are available [6]. Molecular
docking is one of the most applied virtual screening methods and has become
increasingly useful overtime on account of immense growth in 3D X-ray and NMR
structures and their improved resolution (physics and knowledge based docking
algorithms depend on it) reported in the Protein Data Bank (PDB). As an example,
in total 46,541 X-ray structures were reported at the end of 2008 in PDB, but by the
end of 2018 it had grown to a staggering figure of 131,993 [7]. In addition, it is a
resource saving technique which provides accessibility of screening to academia and
small industries which were earlier limited to large pharmaceutical giants.
In this chapter, we will discuss a particular class of molecular design, i.e.,
“Docking” along with the various algorithms, techniques, success stories and limi-
tations related to it. In the end, we will conclude with its scope in the near future.
2. Molecular docking
Two molecules can interact in a number of ways let alone the interaction of a
protein and protein or a protein and small molecule. Molecular docking helps us in
predicting the intermolecular framework formed between a protein and a small
molecule or a protein and protein and suggest the binding modes responsible for
inhibition of the protein. To accurately carry out docking studies one requires the
high-resolution X-ray, NMR or homology-modeled structure with known/predicted
binding site in the biomolecule. To date, 148,827 are available in the database (PDB)
[3]. Docking methods fit a ligand into a binding site by combining and optimizing
variables like steric, hydrophobic and electrostatic complementarity and also
estimating the free energy of binding (scoring) [8].
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There are two basic components which distinguish the variety of docking soft-
wares available to choose from—One is sampling algorithm and the other is scoring
function, these are discussed in detail.
2.1 Sampling algorithm
As pointed out earlier, there are a huge number of modes of binding between
two molecules and even with advances in parallel computing and higher clock
speeds of modern computers it would be expensive and time-consuming to generate
all the possible modes. Therefore, algorithms were needed which could fish out
valuable conformations from the fruitless ones.
Various algorithms were developed in this regard and can be classified by the
number of degrees of freedom they ignore. The simplest of the algorithms intro-
duced treated the molecules as two rigid bodies thereby reducing the degree of
freedom to just six (three translational and three rotational). A very well cited
example of a program using this algorithm is DOCK [9]. This program was designed
to find molecules which had a huge extent of shape similarity to the pockets/
grooves or binding sites. It derives an image of suspected binding sites present on
the surface of the protein. This image consists of several overlapping spheres of
varying radii which touch the molecular surface of the macromolecule at just two
points. The ligand molecule is also considered as a set of spheres which approxi-
mately fill the space occupied by the ligand. Once the respective representations of
the protein surface and the ligand in terms of sphere are complete, the pairing rule
is applied. The pairing rule is based on the principle that ligand sphere can be paired
with a protein sphere if the internal distances of all the spheres in the ligand set
match all the internal distances within the protein set, allowing some user specified
tolerance. Thus, it allows the program to identify geometrically similar cluster of
spheres on the protein site and the ligand. Many other programs were developed
later which make use of such matching algorithm (MA) which include LibDock [8],
LIDAEUS [10], PhDOCK [11], Ph4DOCK [12], Q-fit [13], SANDOCK [14], etc.
All these programs based on MA have the advantage of speed but have several
limitations such as prior need for detailed receptor geometry and lack of molecular
flexibility which does not accurately define many aspects of ligand-protein
interactions.
The second algorithm is that of incremental construction (IC), wherein the
ligand is fragmented from rotatable bonds into various segments. One of the seg-
ments is anchored to the receptor surface. The anchor is generally considered to be
the fragment which shows maximum interactions with the receptor surface, has
minimum number of alternate conformations and fairly rigid such as the ring
system. Once the base/anchor has been established, the next step is to add each of
the fragments step by step. Ideally, those fragments are added first which have a
greater chance of showing interactions like hydrogen bonding since they are direc-
tional in nature and are responsible for specificity of the ligand. In addition, hydro-
gen bonds lead to more accurate prediction of geometry. Once a particular fragment
is added, the poses with the least energies are considered for the next iteration,
making the algorithm extremely fast and robust [15]. IC has been used in programs
like DOCK 4.0 [16], FlexX [15], Hammerhead [17], SLIDE [18] and eHiTS [19],
SKELGEN [20], ProPose [21], PatchDock [22], MacDock [23], FLOG [24], etc. One
major limitation of this program is that it is restricted to medium sized ligands and
is not feasible for large size ligands where the number of fragments generated pose a
problem.
Another useful algorithm is the Monte Carlo (MC) technique. In this approach, a
ligand is modified gradually using bond rotation and translation or rotation of the
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entire ligand. More than one parameter can also be changed at a time to get a
particular conformation. That conformation is then evaluated at the binding site
based on energy calculation using molecular mechanics and is then rejected or
accepted for the next iteration based on Boltzmann’s probability constant. Accep-
tance or rejection of the conformation is a function of the change in energy with
respect to a parameter T, which can be physically interpreted as temperature (sim-
ulated annealing). This criterion of acceptance or rejection makes this method
strikingly different than the others. Whereas the other algorithm favor decrease in
energy, in MC method increases are also possible. For higher values of T increases
are likely. If one starts at a high value of T, then small energy barriers can be jumped
and the configuration can move beyond local minima and is therefore particularly
useful in situations where a global minimum is sought among many local minima
[25]. An interesting spin-off of the MC approach is the Tabu search, which main-
tains a record of the search space of the binding site which has already been visited
and thus ensures that the binding site is explored to the maximum [26]. MC
approach has been made use of in programs like DockVision 1.0.3 [25], FDS [27],
GlamDock [28], ICM [29], MCDOCK [30], PRODOCK [31], QXP [32],
ROSETTALIGAND [33], RiboDock [34], Yucca [35], AutoDock [36], etc. One of
the major concerns with MC approach is the uncertainty of convergence, which can
be improved by performing multiple independent runs.
Genetic algorithm (GA) is quite similar to MC method and is basically used to
find the global minima [37]. These are much inspired by the Darwin’s Theory of
Evolution [38]. GA maintains a population of ligands with an associated fitness
determined by the scoring function. Each ligand represents a potential hit. The GA
alters the ligands of the population by mutation or crossover. In the first stage, a
new population is created by accessing and then selecting the more fit ligands from
the previous step. The members of the populations are then transformed in the
alteration step. The mutation operator creates new ligands from a single ligand by
randomly changing a fragment in its representation while the crossover operator
exchanges information between two (occasionally more) members of the popula-
tion [39–41]. GA has been incorporated in programs like Autodock 4.0 [42], DAR-
WIN [43], DIVALI [39], FITTED [44], FLIPDock [45], GAMBLER [46], GAsDock
[47], GOLD 3.1 [48], PSI-DOCK [49]. GA has a similar limitation like that of MC
method wherein the uncertainty of convergence is a major drawback.
Another approach is the hierarchical method. In this approach, the low energy
conformations of the ligand are pre-computed and aligned. The populations of the
pre-generated ligand conformations are merged into a hierarchy such that similar
conformations are positioned adjacent to each other within the hierarchy. After-
wards, on carrying out rotation or translation of the ligand, the docking program
will make use of this hierarchical data structure and thus minimize the outcomes.
Let us understand with a simple example—if an atom near the rigid center of the
ligand is found to clash with the protein in a given rotation/translation, then this
approach can reject all of the conformations lying below in the hierarchy to that of
the conformation under scrutiny, because the descendants must contain the same
clash as well [50]. GLIDE software makes use of the hierarchical method [51, 52].
2.2 Scoring functions
Sampling changes among varying degrees of freedom must be performed with
sufficient accuracy to identify a conformation that best matches the receptor struc-
ture, and also must be fast enough to permit the evaluation of millions of com-
pounds in a set computational time. This is taken care by the variety of algorithms
discussed above. Algorithms are further complemented by scoring functions.
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The evaluation and ranking of predicted ligand conformations is a crucial aspect
of VS. When we are interested in only how a single ligand binds to a biomolecule,
then the scoring function needs to predict the docked orientation which most accu-
rately represents the “true” structure of the intermolecular complex. On the other
hand, if we are interested to evaluate multiple ligands, in that scenario the scoring
function should not only identify the “true” docking pose but also be able to rank one
ligand relative to another. Therefore, the design of reliable scoring functions and
schemes which can rank different poses is of fundamental importance [53].
The scoring functions usually estimate binding energy of complex using many
assumptions and simplifications to arrive as close as possible to actual binding
energy in minimum time. Popular scoring functions have an adequate balance
between accurate estimation of binding energy and computational cost in terms of
time. There have been a number of scoring functions developed over the past many
years and can be classified into three main categories—force field, empirical and
knowledge based [54].
Force field functions: force field (FF) scoring functions are developed based on
physical atomic interactions like van der Waals interactions, electrostatic interac-
tions and bond lengths, bond angles and torsions [55]. Force field functions and
parameters are usually derived from both experimental data and ab initio quantum
mechanical calculations according to the principles of physics.
E ¼ ∑
i
∑
j
Aij
r12ij

Bij
r6ij
þ
qiqj
ε rij
 
rij
 !
(1)
Here, rij stands for the distance between protein atom i and ligand atom j, Aij and
Bij are the van der Waal parameters, qi and qj are the atomic charges and ε(rij) is the
distance dependent dielectric constant.
One common example of a FF scoring function is that of the program DOCK
[56] represented in Eq. (1), where, the effect of solvent is indirectly considered by
the distance dependent dielectric constant e(rij) seen in the Coulombic potential.
One major drawback of this function is that it does not consider an important
solvent effect that charged groups favor aqueous environments whereas non-polar
groups tend to stay in non-aqueous environments, commonly referred to as the
desolvation effect [57]. Ignorance could lead to biased results as the function would
now be totally dependent on the coulombic interactions and would thus favor
highly charged ligands. In other words, it only takes into account the interaction of
protein and ligand, which is inadequate. To build a more robust function one needs
to also evaluate how both interact with water before the formation of the complex
and how water mediates this process.
Later the Shoichet group [58] improved upon the existing function by adding the
effects of the solvent on protein-ligand interactions using implicit solvent models.
They employed the Poisson-Boltzmann approach to model the electrostatic potential
of the protein. The van der Waals interactions were calculated using the Lennard-
Jones potential; the electrostatic interaction between the ligand and the protein was
estimated using a precomputed receptor potential determined with DelPhi [59].
Ligand desolvation penalties were calculated with HYDREN [60]. The solvent-
corrected scores were found to be closer to experimental binding free energies than
the DOCK program scores, but were still too favorable. The overestimation of
complex stability could be due to the neglect of solute entropic terms [58].
There a few scoring functions which be classified in this category such
as DockScore [56], GoldScore [61], HADDOCK Score [62], ICM SF [29],
QXP SF [32], etc.
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Empirical scoring functions: the basis of this scoring function is that the binding
energies of a complex can be approximated by a sum of individual uncorrelated
terms. The coefficients of the various terms involved in calculation of binding
energy are obtained from regression analysis using experimentally determined
binding energies or potentially from X-ray structural information. Empirical func-
tions have simpler energy terms to evaluate when compared to force field scoring
functions and thus are much faster in binding score calculations.
The first empirical scoring function developed to predict binding free energies
was implemented in LUDI, credited to the pioneering work of Bohm [63]. The
energy was derived using experimental binding free energies and protein-ligand
crystal structures for 45 complexes.
∆Gbind ¼ ∆GO þ ∆Ghb ∑
hbonds
f ∆R;∆αð Þ þ ∆Gionic ∑
ionic int:
f ∆R;∆αð Þ þ ∆Glipo Alipo
 
þ ∆GrotNROT:
(2)
Here, ∆Go is the binding energy independent of protein interactions, ∆Ghb
describes contribution to binding energy from hydrogen bonds, ∆Gionic denotes con-
tribution to binding energy from unperturbed ionic interactions, ∆Glipo considers
contribution to binding energy through lipophilic interactions while Alipo is the lipo-
philic contact surface between the protein and the ligand, ∆Grot describes the loss of
binding energy due to freezing of internal degrees of freedom in the ligand while
NROT represents number of rotatable bonds and f(∆R, ∆α) is a penalty function that
accounts for large deviations from ideal hydrogen bond and salt bridge geometry.
As shown in Eq. (2), the binding free energy is modeled using hydrogen bonds,
salt bridges, the hydrophobic effect, and solute entropy terms. The hydrogen bond
and salt bridge terms are modified by a penalty function which accounts for devia-
tion from ideal geometry. Entropy loss of the ligand upon complex formation is
based on the Number of ROTatable bonds (NROT) in the ligand [64, 65]. Eldridge
et al. presented an empirical scoring function referred to as ChemScore by taking
into account different energetic parameters like hydrogen bonds, the lipophilic
effects of atoms, the effective number of rotatable bonds in the ligand among
others. The scoring function was calibrated using 82 ligand-receptor complexes
with known binding affinities [66].
By including different empirical energy terms, many different empirical scoring
functions have been developed such as SCORE2 [67], ChemScore [66], RankScore
[68], LigScore [69], GlideScore [51], HINT [70], etc. The empirical scoring func-
tions take into account many different energy terms and thus the problem of
unknowingly double-counting of certain energy terms difficult issue to tackle.
Knowledge based scoring functions: these are derived from the structural infor-
mation embedded in experimentally determined atomic structures. The functions
use statistical analysis on crystal structures of complexes to obtain the interatomic
contact frequencies between the protein and the ligand based on the presumption
that stronger an interaction is, the greater the frequency of its occurrence will be.
The overall score is calculated with the help of Eq. (3) by accounting for favorable
contacts and repulsive interactions between each atom in the ligand and protein
lying within a sphere with a specified cutoff [71–78].
w rð Þ ¼ kBTln g rð Þ½ , g rð Þ ¼ rð Þρ rð Þ=ρ ∗ rð Þ (3)
Here, kB is the Boltzmann constant, T is the absolute temperature of the system,
ρ(r) is the number density of the protein-ligand atom at distance r, ρ*(r) is the pair
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density in the reference state where interatomic interactions are zero and g(r) is
pair distribution function.
Popular knowledge based functions include DrugScore [79], PMF [72, 80],
MScore [81], SMoG [71], BLEEP [74], ITScore/SE [75], etc. The computational
simplicity of such functions is a major advantage especially when one has large
databases at hand however, the accuracy of predicting the reference state and
underrepresentation of interactions with halogens and metals are the major hurdles.
Each of the above classified have their inherent drawbacks, in this regard,
combination of more than one scoring functions has given improved results. This
approach has been widely regarded as “Consensus Scoring” [46].
Another set of scoring functions which have recently started to attract attention
are based on machine learning. One of the programs based on functions incorpo-
rating machine learning was able to achieve an astounding hit rate of 88.6% [82].
The nexus of machine learning and scoring functions is promising but the develop-
ment of such a tool is slow owing to its complexity.
In order to compare the variety of scoring functions that have been developed
up until now, comparative assessment of scoring functions (CASF) is an incredible
platform to begin with [83].
There is another set of classification proposed for the scoring functions namely
physics-based methods, empirical scoring functions, knowledge-based potentials,
and descriptor-based scoring functions but there is still no clear consensus on which
classification of scoring functions would be appropriate [84].
3. Applications
Molecular docking has been developed and improving for many years, but its
ability to generate a viable drug is still generally questioned. In the section below,
you will find examples where docking approach lead to recognition of active hits for
a variety of different receptors/targets.
HIV 1 Integrase—a new binding site for drugs treating AIDS was discovered
by Schames et al. using docking while considering the flexibility of the receptor
through molecular dynamics. The group used AutoDock in conjunction with
the relaxed-complex method to discover novel mode of inhibition of HIV
integrase [85].
α1A Adrenergic receptor—Evers et al. generated a model of the receptor using
homology modeling based on the X-ray crystallographic structure of bovine rho-
dopsin. Hierarchical virtual screening method was performed by them on the
Aventis in-house compound repository in a stepwise manner. 22,950 filtered com-
pounds were then docked into the α1A receptor homology model with the program
GOLD and scored with PMF. The top scoring compounds were finally clustered
according to their unity fingerprint similarity, and a diverse set of 80 compounds
was tested in a radio ligand displacement assay. Thirty-seven compounds displayed
a Ki < 10 μM with the most active having Ki = 1.4 nM [86].
Type I TGF-beta receptor kinase—A striking example and a proof of the benefit
of in silico approach over classical high-throughput screening involves the discov-
ery of novel Type I TGF-beta receptor kinase inhibitor. The same molecule (HTS-
466284); Figure 1, a 27 nM inhibitor, was discovered independently using virtual
screening [87] and also by traditional enzyme and cell-based high-throughput
screening in the same year [88]. The compound discovered experimentally required
in vitro screening of a large library of compounds in a TGF-β-dependent cell-based
assay which required more time, proved to be costlier and required usage of a
variety of chemicals when compared to its computational counterpart.
7
Molecular Docking in Modern Drug Discovery: Principles and Recent Applications
DOI: http://dx.doi.org/10.5772/intechopen.85991
Aurora Kinase A—A major improvement was seen in the inhibitory activity of
Aurora Kinase A inhibitors which were designed using in silico techniques by Park
et al. [89]. This research group made use of a genetic algorithm to carry out the
sampling while the scoring function involved the energy terms from the AutoDock
program with a slight modification of the dehydration energy term. The design
strategy and tools used to carry out the study proved to be immensely successful
with some inhibitors revealing exceptionally high potency at low picomolar levels;
Figure 2 [89].
Dopamine D3 receptor—The 3D structure of the Dopamine 3 (D3) subtype
receptor was modeled by Varady et al. from the X-ray crystallographic structure of
rhodopsin and validated using experimental data. A D3 pharmacophore model was
devised by them from 10 selective and potent known D3 receptor ligands. Using
their model, 250,251 compound were screened from the National Cancer Institute
(NCI) 3D database. The hit list of 2478 potential ligands was then filtered for known
chemotypes. After removal of all compounds that were structurally similar to
known D3 receptor ligands, 1314 candidates remained. At the end, 20 compounds
supplied by NCI to the group were tested, out of which eight had Ki values below
500 nM, among which one of the compounds had Ki = 11 nM; Figure 3 [90].
Serotonin receptor (5HT1A)—Due to lack of structural information available for
the receptor, Becker et al. made use of PREDICT, to develop a unique non-
homology model for building a virtual 3D structure of the receptor. Using the
model, 40,000 compounds from Predix’s compound library were screened for
molecular docking and 78 virtual hits were discovered and then purchased by them
from respective vendors. The in vitro 5-HT1A binding assays elucidated that 16 of
the 78 compounds tested by the group were found to be hits with Ki < 5 μM,
reflecting a 21% hit rate, 9 of which had a Ki < 1 μM. The most potent molecule had
Ki = 1 nM (Figure 4) and was selected as a lead molecule for further optimization.
One significant feature of the study which highlights the utility of docking was that
Figure 1.
Structure of HTS-46628, type I TGF-beta receptor kinase inhibitor.
Figure 2.
Structures for Aurora Kinase A inhibitor with IC50 12 and 43 pM respectively.
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the complete discovery process, i.e., from in silico screening through lead optimi-
zation, preclinical, and into clinical studies, was very rapid, requiring less than a
couple of years from program initiation to Phase I clinical trial [91].
Crystal structure prediction challenge—The International Blind Test is a chal-
lenge organized by the Cambridge Crystallographic Data Center wherein a previ-
ously determined crystal structure is only revealed once all the participants submit
their respective structures. In the Fifth International Blind Test, the challenge was
toughened by including flexible molecules with 50–60 atoms. The successful pre-
diction by two participants of the crystal structure of molecule XX in the blind test
indicated that search methods and models for lattice energy are capable of provid-
ing worthwhile results, both in terms of the range of structures considered in the
search and relative energies of the structures and thus can act as efficient ranking
systems [92].
Muscarinic M3 receptor—A pharmacophore model was constructed by Marriot
et al. from the known molecules showing significant M3 potency [93]. The research
group utilized the program DISCO, which generated five models. Three models
were rejected based on structural overlay. 3D screening was performed by Unity 3D
of the Astra compound database. The first model developed by them gave 176 hits
while the second model gave 173 hits; 172 compounds were common to the two sets
and were tested for their M3-antagonistic potency. Several compounds with
Figure 3.
Structure of dopamine D3 receptor inhibitor with Ki = 11 nM.
Figure 4.
Structure of serotonin receptor inhibitor with Ki = 1 nM.
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micromolar and even submicromolar activities resulted, for example, compound
below had A50 M3 antagonism ≈ 0.2 μM; pA2 = 6.67; Figure 5 [93].
Checkpoint Kinase 1—Lyne et al. utilized virtual screening to discover Check-
point Kinase 1 (Chk-1) inhibitors [94]. Compounds with molecular weight > 600 or
with more than 10 rotatable bonds were excluded from the database. Then 3D
structures of the ligands were generated using Corina and a maximum of 8 stereo-
isomers were generated for each molecule. A 3D pharmacophore search was
performed with their in-house program Plurality to eliminate compounds that do
not have the typical binding motif for the kinase region. The remainder of the
compounds were docked into the ATP binding site of Chk-1, using the program
FlexX-Pharm, which considers full flexibility of the ligand but treats the protein as a
rigid structure. The research group then utilized consensus scoring to identify
molecules which were consistently giving good score with different scoring func-
tions. Finally, visual inspection by the group of the 250 highest scoring hits for
unfavorable interactions with the binding site or compounds with unrealistic con-
formations resulted in a list of 103 compounds for biological testing. Thirty-six hits
were identified with IC50 ranging from 110 nM to 68 μM; Figure 6 [94].
Human Cathepsin K—Schröder et al. presented the implementation of a
docking-based virtual screening workflow for the retrieval of covalent binders,
human cathepsin K was utilized as a test case [95]. By using the filter of electrophilic
war heads, a database with two million structurally diverse compounds with a
Figure 5.
Structure of muscarinic M3 receptor antagonist.
Figure 6.
Structures of checkpoint kinase 1 inhibitor with IC50 450 nM and 4 μM respectively.
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variety of functional groups was reduced to a data set of just 343 test compounds.
Molecular docking was performed by them and the top scoring poses of the
GoldScore ranking list were taken into account for the manual selection of the
virtual hits based on visual inspection of the appropriate fit of the molecule in the
active site. A data set of 44 compounds including the five low scoring compounds
were finally selected for experimental evaluation. The activity of 21 out of the
selected 39 in silico hits was experimentally confirmed and four out of the five
structures predicted as inactive showed no activity on cathepsin K. This study
demonstrated to a huge extent the ability of docking to generate positive outcomes
(Figure 7) [95].
Human aldose reductase (ALR2)—ALR2 catalyzes a key reaction in the polyol
pathway of glucose metabolism, a process implicated in the long-term complica-
tions of diabetes. Its inhibitors were designed by Wang et al. using molecular
dynamic (MD) simulations and virtual screening [96]. A major challenge encoun-
tered by them in the in silico studies was that the binding site of the enzyme
underwent large conformational changes and adopted distinct configurations upon
binding different classes of ligands. To address this issue, the group sampled poten-
tially accessible binding site conformations by MD simulations based on the avail-
able crystallographic structures of ALR2. After this procedure, three average
conformations were selected for the docking. FlexX was utilized to carry out
docking of 7200 compounds of which 128 compounds were selected by them for
further screening. Out of these 72 molecules were selected which had RMSD < 3.00
A for experimental assay, of which 15 novel ALR2 inhibitors hits were discovered.
The most potent inhibitor had an IC50 = 0.24 μM; Figure 8 [96].
Cyclooxygenase-2 (COX-2) and β-amyloid aggregation inhibitors—Dadashpour
et al. made use of AutoDock4.2 to carry out docking studies of designed molecules
Figure 7.
Respective structures for active and inactive covalent binders of human cathepsin K.
Figure 8.
Structure of human aldose reductase inhibitor with IC50 = 0.24 μM.
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based on diaryltriazine as lead. To validate the enzyme-inhibitor complex, the key
molecular interactions and calculated binding energy were considered by them.
Among the designed molecules, one of the compounds (Figure 9) showed an IC50
of 10.1 μM in experimental COX-2 assay. In addition, it showed potent anti-
aggregation activity on β peptides [97].
4. Limitations
The major limitation of molecular docking is due to the lack of confidence on the
ability of scoring functions to give accurate binding energies. This stems from the
fact that some intermolecular interaction terms are hardly predicted accurately,
such as solvation effect and entropy change [98]. In addition, some intermolecular
interactions are rarely considered in scoring functions which have been proven to
be of significance. For instance, halogen bonding is verified to make a contribution
to protein-ligand binding affinity [99] and so do guanidine-arginine interactions
[100], but are not considered.
Transthyretin-thyroxine complex—One critical example wherein energy func-
tions failed is that of transthyretin-thyroxine complex. The docking simulations
with energy functions resulted in generation of two binding modes, one similar to
the native binding mode of thyroxine and the other belonging to an alternate
binding domain with a root mean square deviation (RMSD) of 8.97 Å from native
binding state. The energy simulation was carried out and the lower energy solution
picked by the docking program was the one with higher RMSD. Thus, in this case
molecular docking failed to make the correct prediction of binding mode. Thereby,
it would be fair to conclude that we might get many false negatives during the
process of VS. [101].
It is still an unsolved problem to accurately deal with the water molecules in
binding pocket during docking process, which is tough task and needs a lot of
attention in the near future due to two reasons. Firstly, the x-ray crystal structures
lack the coordinate information of hydrogen, due to inefficient scattering by
smaller atoms. Not knowing the exact position of hydrogen leads to inaccuracies in
identifying water molecules which might be acting as a bridging molecule between
the ligand and the receptor. Secondly, no reliable theoretical approach is available
to accurately predict how water molecules are affected by ligands and how strong
the effect is. On top of that, it impossible with our current knowledge to predict
how many water molecules in the binding pocket would be replaced by potential
ligands and how the hydrogen bonding network would be disturbed by ligand
binding [102].
Figure 9.
Structure of cyclooxygenase-2 inhibitor with IC50 = 10.1 μM.
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One of the major challenges faced in the field of docking is that of rigid receptor.
A protein can adopt many different conformations depending upon the ligand to
which it binds. As a result, docking performed using a rigid receptor will corre-
spond to a single receptor conformation, which leads to false negatives in many
cases where later the ligand was found to be active. This happens because a protein
can exist in constant motion between different conformational states having similar
energies, which is usually neglected in docking [58].
Finally, the spectrum of activity against off-target proteins is something rarely
seen even in computational screens and is only dealt by animal and human trials.
5. Conclusion
Thus, it is quite evident from the case studies highlighted above and many more
success stories that one can find in literature related to computer aided drug design,
that in silico approaches in combination with biophysical data, experimental high
throughput screening and biology/toxicology/clinical studies are an indispensable
tool in the process of drug discovery. It assists in decision making, conceptualizing
new ideas and exploring them in a rapid manner to test a hypothesis, bringing
solutions to problems that cannot be assessed experimentally either because the
experiments is too difficult to design or because it would cost too much.
Undoubtedly, many challenges still remain to be addressed such as role of water
molecules, solvent effects, entropic effects, and receptor flexibility.
There is more than sufficient information now that proves the utility of compu-
tational tools in drug design and there is no scope for any debate regarding the
effectiveness and advantage of computational tools in the process of drug discovery.
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